A Study of Bimatoprost 0.01% in the Clinical Setting
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This is a study of bimatoprost 0.01% (LUMIGAN® 0.01%) in subjects with primary open-angle
glaucoma (POAG) or ocular hypertension (OH) who require further treatment for elevated
intraocular pressure (IOP).